Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?

Table 2 Baseline ocular characteristics of the patients in each group

		Control group	NPDR group	PDR group	P-value
Baseline netrin-1 (pg/ml)	mean ± SD	983 ± 664	253 ± 75	318 ± 68
Baseline netrin-1 (pg/ml)	median (IQR)	737 (597–931)	245 (216–321)	301 (272–323)	< 0.001^a
Baseline VEGF (pg/ml)	mean ± SD	203 ± 137	197 ± 78	388 ± 232
Baseline VEGF (pg/ml)	median (IQR)	157 (122–263)	184 (155–217)	320 (288–377)	0.001^a

NPDR Non-proliferative diabetic retinopathy, PDR Proliferative diabetic retinopathy, IQR Interquartile range, SD Standard deviation, VEGF Vascular endothelial growth factor. Note: ^aKruskal-Wallis Test

ISSN: 1471-2415